Core Viewpoint - The company reported a significant increase in revenue and net profit for the first half of 2025, driven by strong sales of methionine and vitamins, despite a slight decline in gross margin [1][3]. Financial Performance - The company's revenue for the first half of 2025 was 8.512 billion yuan, a year-on-year increase of 17.23% - Net profit attributable to shareholders was 740 million yuan, up 21.82% year-on-year - The gross profit margin for the first half of 2025 was 28.41%, a decrease of 2.95 percentage points compared to the same period in 2024 - Financial expenses increased by 175.14% year-on-year, primarily due to increased interest income and foreign exchange impacts [1][2] Cash Flow and Working Capital - Net cash flow from operating activities was 1.450 billion yuan, up 17.82% year-on-year - Net cash flow from investing activities was -1.221 billion yuan, a decrease of 75.05% year-on-year, mainly due to accelerated construction of projects - The ending balance of cash and cash equivalents was 1.459 billion yuan, an increase of 42.37% year-on-year - Accounts receivable increased to 2.082 billion yuan, up 4.12% year-on-year, with an improved turnover rate [2] Product Performance - The functional products segment generated revenue of 6.47 billion yuan, a year-on-year increase of 20.03% - The methionine segment showed a steady recovery in market prices, with sales volume increasing significantly, particularly in liquid methionine [3] - The vitamin segment benefited from increased sales of Vitamin A and E, offsetting price pressures in the second quarter [3] Strategic Development - The company is solidifying its leadership position in the methionine industry and advancing its dual pillar strategy with a focus on specialty products - The construction of a 150,000-ton solid methionine plant in Quanzhou is progressing smoothly, with plans for a liquid methionine plant in Europe to be operational by the end of 2025 [4] - The specialty products segment includes a diverse range of products, with a strong focus on ruminant products and enzyme preparations, aiming for financial growth by 2027 [5] Investment Outlook - The company is expected to achieve revenues of 17.288 billion yuan, 19.026 billion yuan, and 20.552 billion yuan for 2025-2027, with corresponding net profits of 1.714 billion yuan, 1.944 billion yuan, and 2.216 billion yuan - The growth is supported by increasing sales in methionine and vitamins, alongside the company's ongoing efforts to enhance its competitive position through the dual business strategy [6]

Core Viewpoint - The company announces the implementation of an online voting reminder service for its upcoming shareholder meeting to enhance participation among small and medium investors [1][2]. Group 1: Shareholder Meeting Details - The company will hold its third extraordinary general meeting of 2025 on September 25, 2025, at 14:00, utilizing both on-site and online voting methods [1]. - The notice regarding the shareholder meeting was previously disclosed on September 10, 2025 [1]. Group 2: Voting Reminder Service - The company will employ the Shanghai Stock Exchange Information Network Co., Ltd. to provide a reminder service for shareholders, ensuring timely participation and voting [1]. - Shareholders will receive proactive notifications via smart SMS about the meeting and voting details based on the shareholder registry date [1]. - Investors can vote directly through the provided manual after receiving the SMS, and alternative voting methods remain available in case of congestion [1].

Core Viewpoint - The company announced its plan to utilize the shareholder meeting reminder service provided by Shanghai Stock Exchange Information Co., Ltd. to enhance shareholder engagement and participation in voting [2] Group 1 - The company will delegate the reminder service to Shanghai Stock Exchange Information, which will use smart messaging to notify shareholders [2] - The service will actively remind shareholders to attend and vote at the meetings based on the shareholder register as of the record date [2] - Each investor will receive invitations and information regarding the meeting agenda through proactive notifications [2]

蓝星安迪苏股份有限公司 2025 年第三次临时股东大会会议资料 蓝星安迪苏股份有限公司 2025 年第三次临时股东大会 会议资料 二零二五年九月二十五日 1 蓝星安迪苏股份有限公司 2025 年第三次临时股东大会会议资料 蓝星安迪苏股份有限公司 2025 年第三次临时股东大会 重要提示： 现场会议时间：2025 年 9 月 25 日（星期四）下午 14:00 会议地点：北京市朝阳区北土城西路 9 号蓝星大厦会议室 主持人：董事长郝志刚 参加会议人员： | | | 1. 在股权登记日持有公司股份的股东 2. 本次股东大会的股权登记日为 2025 年 9 月 18 日，于股权登记日下午收市时 中国证券登记结算有限责任公司上海分公司登记在册的公司股东均有权出 席股东大会，并可以以书面形式委托代理人出席会议和参加表决。该代理人 不必是公司股东 3. 公司董事、监事和高级管理人员 4. 公司聘请的律师 蓝星安迪苏股份有限公司 2025 年第三次临时股东大会会议资料 蓝星安迪苏股份有限公司 2025 年第三次临时股东大会 会议须知 蓝星安迪苏股份有限公司 董事会办公室 3 | 议程 | | | --- | --- | | ...

证券代码：600299 证券简称：安迪苏 公告编号： 2025-044 蓝星安迪苏股份有限公司 关于股东大会开设网络投票提示服务的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 蓝星安迪苏股份有限公司（以下简称"安迪苏"或"公司"）已于 2025 年 9 月 10 日披露了关于召开 2025 年第三次临时股东大会的通知，拟于 2025 年 9 月 25 日下午 14:00 召开 2025 年第三次临时股东大会，本次会议采用现场投票和网络 投票相结合的表决方式。具体内容详见公司披露于上海证券交易所的公告《安 迪苏关于召开 2025 年第三次临时股东大会的通知》（公告编号：2025-042）。 为更好地服务广大中小投资者，确保有投票意愿的中小投资者能够及时参 会、及时投票。公司拟使用上证所信息网络有限公司（以下简称"上证信息"） 提供的股东大会提醒服务，委托上证信息通过智能短信等形式，根据股权登记 日的股东名册主动提醒股东参会投票，向每一位投资者主动推送股东会参会邀 请、议案情况等信息。投资者在收到智能短信后，可根据使用手册 ...

Core Viewpoint - Andy Su's stock price has experienced a decline of 22.39% year-to-date, with a recent drop of 2.04% on September 15, 2023, indicating potential concerns regarding its market performance and investor sentiment [1]. Financial Performance - For the first half of 2025, Andy Su reported a revenue of 8.512 billion yuan, reflecting a year-on-year growth of 17.23%, and a net profit attributable to shareholders of 740 million yuan, which is a 21.82% increase compared to the previous year [2]. - The company has distributed a total of 4.936 billion yuan in dividends since its A-share listing, with 1.049 billion yuan distributed over the last three years [2]. Shareholder and Market Activity - As of June 30, 2025, the number of shareholders for Andy Su decreased by 5.24% to 32,700, while the average number of circulating shares per person increased by 5.53% to 82,035 shares [2]. - The stock's trading activity on September 15, 2023, showed a net outflow of 8.5654 million yuan from major funds, with significant selling pressure observed [1]. Company Overview - Andy Su, established on May 31, 1999, and listed on April 20, 2000, specializes in the research, production, and sales of animal nutrition additives, with functional products accounting for 76.07% of its revenue and specialty products making up 23.93% [1]. - The company is categorized under the basic chemicals industry, specifically in food and feed additives, and is associated with several concepts including state-owned enterprise reform and vitamins [1].

Group 1 - The stock price of Andy Su (600299) closed at 9.8 yuan on September 12, 2025, reflecting a 0.2% increase from the previous week's 9.78 yuan, with a market capitalization of 26.39 billion yuan [1] - The company ranks 11th out of 169 in the chemical products sector and 709th out of 5153 in the A-share market [1] Group 2 - Andy Su will hold its third extraordinary general meeting of shareholders on September 25, 2025, to discuss several resolutions, including the cancellation of the supervisory board and amendments to the company's articles of association [2] - The meeting will be conducted both in-person and via online voting, with the record date set for September 18, 2025 [2] Group 3 - The company has received approval from the China Securities Regulatory Commission for its application to issue shares to specific targets, with the registration valid for 12 months from the date of approval [3] - The issuance will not change the company's control and has been approved by the Shanghai Stock Exchange [6] Group 4 - Andy Su plans to raise up to 3 billion yuan through the issuance of shares, which will be allocated to various projects, including a solid methionine project and special feed additive projects [5] - The funds will also be used for wastewater treatment and working capital [5]

蓝星安迪苏股份有限公司 向特定对象发行 A 股股票 募集说明书 （注册稿） 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期） 北座 二〇二五年九月 股票简称：安迪苏 股票代码：600299 蓝星安迪苏股份有限公司 向特定对象发行 A 股股票募集说明书（注册稿） 声 明 本公司及全体董事、监事、高级管理人员承诺募集说明书及其他信息披露 资料不存在任何虚假记载、误导性陈述或重大遗漏，并对其真实性、准确性及 完整性承担连带赔偿责任。 公司负责人、主管会计工作负责人及会计机构负责人保证募集说明书中财 务会计资料真实、完整。 中国证券监督管理委员会、上海证券交易所对本次发行所作的任何决定或 意见，均不表明其对申请文件及所披露信息的真实性、准确性、完整性作出保 证，也不表明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质 性判断或保证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由 发行人自行负责。投资者自主判断发行人的投资价值，自主作出投资决策，自 行承担证券依法发行后因发行人经营与收益变化或者证券价格变动引致的投资 风险。 1- ...

Core Viewpoint - The approval of Andy Su's 3 billion yuan private placement aims to enhance production capacity and support sustainable development projects, reflecting the company's growth strategy in the animal nutrition sector [1][2]. Fundraising and Business Expansion - Andy Su plans to raise up to 3 billion yuan through a private placement to expand production capacity and supplement working capital [2]. - The funds will be allocated to functional products, special products, and sustainable development projects, with 1.743 billion yuan specifically earmarked for a solid methionine project [2][3]. - The company categorizes its main products into functional products (including methionine and vitamins) and special products (including feed additives) [2]. Market Demand and Growth - The global demand for methionine is projected to reach 1.7 million tons by 2024, with a compound annual growth rate (CAGR) of 4.4%, while China's demand is expected to grow from 280,000 tons in 2019 to 450,000 tons by 2024, with a CAGR of 10% [3]. - The company anticipates strong market absorption for its new production capacity due to this growing demand [3]. Financial Performance - In the first half of 2025, Andy Su reported a revenue increase of 17.23% to 8.512 billion yuan and a net profit increase of 21.82% to 740 million yuan [4]. - The sales of methionine continued to grow, driven by increased market penetration, with a 16% year-on-year increase in sales volume [4]. - The special products segment also saw a revenue increase of 9% to 2.04 billion yuan, supported by strong sales growth in ruminant and pig products [4]. Research and Development - The company is committed to increasing R&D investments in green production, biotechnology, and digital services, with R&D expenses reaching 172 million yuan in the first half of 2025 [5]. - Andy Su operates five global R&D centers with over 300 employees dedicated to research and innovation, which are crucial for supporting its dual pillar strategy [5].

Core Viewpoint - Company received approval from Shanghai Stock Exchange for a specific stock issuance, which is valid for 12 months from the date of approval [1] Group 1: Stock Performance - As of September 11, 2025, the stock price of Andy Su (600299) closed at 9.82 yuan, an increase of 0.31% from the previous trading day [1] - The stock opened at 9.79 yuan, reached a high of 9.83 yuan, and a low of 9.72 yuan, with a trading volume of 82.97 million yuan and a turnover rate of 0.32% [1] Group 2: Regulatory Approval - Company announced on September 9, 2025, that it received the approval from Shanghai Stock Exchange for the registration of stock issuance to specific investors [1] - The approval is documented under the regulatory number (证监许可〔2025〕1970号) and requires the company to strictly follow the submitted application documents and issuance plan [1] - The company is obligated to complete the issuance-related matters within the stipulated timeframe and fulfill information disclosure requirements [1]